member mufg global financi group
report better expect result morn
total revenu adjust ebitda adjust ep beat high-
end manag guidanc rang estim consensu
out-performance driven solid top-lin growth oper
execut technolog analyt
fundament remain strong continu gener sale
momentum highlight report continu book growth
highest dollar valu histori despit momentum backlog
convert revenu next month remain
unchang prior quarter due long-tail natur
busi believ current valuat fairli reflect
compani medium-term growth outlook maintain neutral
result report adjust ep yoy
guidanc rang our/consensu estim
out-performance larg driven better
expect organ result technolog
analyt solut segment lower tax
revenu total revenu yoy fx adjust
exceed guidanc our/
consensu estim technolog analyt
adjust organ contract sale medic solut
formerli report revenu declin fx
backlog book end backlog includ passthrough
revenu total repres qoq growth
expect convert revenu next twelv
month consist prior quarter ttm net new busi
award book total increas qoq
yoy ttm net book-to-bil increas
ttm backlog coverag increas qoq
ebitda adjust ebitda yoy fx adjust
exceed high-end guidanc
our/consensu estim out-performance
attribut oper execut adjust ebitda margin
increas yoy declin qoq
share
import disclosur analyst certif begin page
debt capit deploy ocf total
increas yoy net debt adjust ebitda
unchang qoq quarter repurchas stock
remain share buy-back author
recent win manag highlight segment
ad new client sinc begin year gross new
busi award increas yoy growth
emerg biopharma space real-world data side compani
report signific win top five pharma client set real-
world data arm europ benchmark result client single-arm
oncolog trial manag also report oce saa busi
three award drug safeti busi two global award
top pharma client grow pharmacovigil market
guidanc total revenu guidanc rang increas
midpoint new rang outlook
adjust ebitda increas midpoint
adjust ep increas midpoint
prior guidanc introduc total
revenu rang yoy growth adjust
ebitda yoy growth adjust ep
estim adjust model reflect out-performance
guidanc new adjust ep estim
yoy adjust ep estim
increas yoy yoy
valuat current trade discount peer group
price-to-earnings basi current valuat fairli reflect iqv
medium-term growth outlook view per share target
base multipl adjust ep estim
dollar share million except ep
compani report research estim bloomberg
oper resultsactualmufgcon guidancemufgcon total bpsadj sg total bpsadjust adj ebitda expens pre-tax adjust tax bpsadjust ni weight average new biz award ttm backlog book bill backlog vs estimate svarianceestim
dollar million except ep compani report musa
incom yoy yoy growth constant revenu ebitda yoy integr revenu purchas acct adj ebitda yoy oper oper debt incom unconsolid attribut pre-tax adjust tax adjust tax incom minor interest effect ni yoy average share yoy us equiti research
believ iqvia benefit industri tailwind around bio-
pharmaceut spend clinic trial outsourc compani
invest real-world insight next-gen cro offer
may translat competit advantag contribut acceler
top-lin growth opportun howev may take time servic
offer evolv contribut revenu earn growth
current trade discount peer group
price-to-earnings basi current valuat fairli reflect iqv medium term
growth outlook view per share target base
multipl adjust ep estim
risk recommend downsid upsid includ
acceler slowdown bio-pharmaceut research
develop gain loss contract chang healthcar
regulatori environ chang reimburs level chang
competit landscap
iqvia world largest clinic research organ cro
provid biopharmaceut client outsourc research
develop product commerci form
merger quintil im health octob iqvia
one largest comprehens collect world-wide
healthcar inform compani expect gener
revenu carri contract backlog excess
